NEUWAY Pharma (Life Science Incubator GmbH spin-off), is a biotech company, focus on the preclinical and clinical development of innovative therapeutics for the treatment of orphan brain diseases based on its proprietary CNS drug delivery platform.
NEUWAY Pharma GmbH
In May 2016, AbbVie, Germany and NEUWAY Pharma partners for three years to analyze, validate and use a new technology based on Engineered Protein Capsules (EPC), to transport highly active substances across the blood-brain barrier.
In Feb 2015, University Zurich and NEUWAY entered into a license agreement to develop Engineered Protein Capsules (EPC) technology to treat progressive multifocal leucoencephalopathy (PML), a rare neurological disease.[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”” connections=”true” suffix=””]
NEUWAY technology platform Engineered Protein Capsules (EPC), allows to pack drug molecules in a virus-like particles to transport them across the blood-brain barrier into the CNS and broadens the range of possible drug delivery options.
In Oct 2016, NEUWAY Receives 2.95 Million Germany`s Federal Ministry of Education and Research (BMBF) Grant for Advancing CNS Drug Delivery Platform .
In Oct 2015, NEUWAY Pharma complete series A financing and raised 5.85 Mn in two rounds. The lead investors includes Wellington Partners, Life Science Inkubator and Kreditanstalt fÈr Wiederaufbau (KfW).